echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Yuandong's first review of 700 million varieties

    Yuandong's first review of 700 million varieties

    • Last Update: 2021-08-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network News, August 18, August 16, NMPA official website showed that Yuandong Bio's naloxone hydrochloride injection passed the consistency evaluation and was the first company to pass the evaluation
    .
    Naloxone hydrochloride is an opioid receptor antagonist, and its terminal sales in China's public medical institutions will exceed 700 million yuan in 2020
    .
    Up to now, 16 varieties of Yuandong Biology have been evaluated (5 are the first ones)
    .
     
     
    Naloxone hydrochloride is an opioid receptor antagonist.
    It is suitable for acute poisoning of narcotic analgesics and acute alcohol poisoning.
    It is also used for respiratory depression and coma caused by known or suspected opioid overdose.
    It can also be used for opioids.
    Differential diagnosis of drug addicts
    .
     
    Meinenet data shows that in 2020, China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sales of naloxone exceed 700 million yuan
    .
    Among them, Chenxin Pharmaceutical, Yuandong Biological, Chengdu Tiantaishan Pharmaceutical and other three companies have a market share of more than 15%
    .
     
      Sales of terminal naloxone in public medical institutions in China (unit: ten thousand yuan)
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      At present, there are 24 manufacturers of naloxone hydrochloride injection in the domestic market, but only Yuandong Biotech has submitted a supplementary application for consistency evaluation
    .
    In addition, Sichuan Meida Kangjiale Pharmaceutical has exclusively submitted an application for the marketing of naloxone hydrochloride injection with imitation 3 types.
    If it is successfully approved, it will be deemed to have been reviewed
    .
     
      Up to now, Yuandong Biology has 16 varieties (31 product specifications) passed/deemed to pass the consistency evaluation, of which 5 varieties are the first to pass the evaluation
    .
     
      Data source: Mi Neiwang database, NMPA
      Medical Network News, August 18, August 16, NMPA official website showed that Yuandong Bio's naloxone hydrochloride injection passed the consistency evaluation and was the first company to pass the evaluation
    .
    Naloxone hydrochloride is an opioid receptor antagonist, and its terminal sales in China's public medical institutions will exceed 700 million yuan in 2020
    .
    Up to now, 16 varieties of Yuandong Biology have been evaluated (5 are the first ones)
    .
     
     
      Naloxone hydrochloride is an opioid receptor antagonist.
    It is suitable for acute poisoning of narcotic analgesics and acute alcohol poisoning.
    It is also used for respiratory depression and coma caused by known or suspected opioid overdose.
    It can also be used for opioids.
    Differential diagnosis of drug addicts
    .
     
      Meinenet data shows that in 2020, China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sales of naloxone exceed 700 million yuan
    .
    Among them, Chenxin Pharmaceutical, Yuandong Biological, Chengdu Tiantaishan Pharmaceutical and other three companies have a market share of more than 15%
    .
     
      Sales of terminal naloxone in public medical institutions in China (unit: ten thousand yuan)
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      At present, there are 24 manufacturers of naloxone hydrochloride injection in the domestic market, but only Yuandong Biotech has submitted a supplementary application for consistency evaluation
    .
    In addition, Sichuan Meida Kangjiale Pharmaceutical has exclusively submitted an application for the marketing of naloxone hydrochloride injection with imitation 3 types.
    If it is successfully approved, it will be deemed to have been reviewed
    .
     
      Up to now, Yuandong Biology has 16 varieties (31 product specifications) passed/deemed to pass the consistency evaluation, of which 5 varieties are the first to pass the evaluation
    .
     
      Data source: Mi Neiwang database, NMPA
      Medical Network News, August 18, August 16, NMPA official website showed that Yuandong Bio's naloxone hydrochloride injection passed the consistency evaluation and was the first company to pass the evaluation
    .
    Naloxone hydrochloride is an opioid receptor antagonist, and its terminal sales in China's public medical institutions will exceed 700 million yuan in 2020
    .
    Up to now, 16 varieties of Yuandong Biology have been evaluated (5 are the first ones)
    .
     
     
      Naloxone hydrochloride is an opioid receptor antagonist.
    It is suitable for acute poisoning of narcotic analgesics and acute alcohol poisoning.
    It is also used for respiratory depression and coma caused by known or suspected opioid overdose.
    It can also be used for opioids.
    Differential diagnosis of drug addicts
    .
     
      Meinenet data shows that in 2020, China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sales of naloxone exceed 700 million yuan
    .
    Among them, Chenxin Pharmaceutical, Yuandong Biological, Chengdu Tiantaishan Pharmaceutical and other three companies have a market share of more than 15%
    .
    Hospital Hospital Hospital Enterprise Enterprise Enterprise
     
      Sales of terminal naloxone in public medical institutions in China (unit: ten thousand yuan)
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      At present, there are 24 manufacturers of naloxone hydrochloride injection in the domestic market, but only Yuandong Biotech has submitted a supplementary application for consistency evaluation
    .
    In addition, Sichuan Meida Kangjiale Pharmaceutical has exclusively submitted an application for the marketing of naloxone hydrochloride injection with imitation 3 types.
    If it is successfully approved, it will be deemed to have been reviewed
    .
     
      Up to now, Yuandong Biology has 16 varieties (31 product specifications) passed/deemed to pass the consistency evaluation, of which 5 varieties are the first to pass the evaluation
    .
     
      Data source: Mi Neiwang database, NMPA
      
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.